By Jason Napodano, CFA
FDA Grants HUD...
InVivo Therapeutics (OTC:NVIV) had a busy last week with respect to FDA approvals and clearances. On April 4, 2013, InVivo announced that the U.S. FDA had approved the company's request for a Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. InVivo requested the agency grant its biopolymer scaffolding orphan status for the treatment of recent complete spinal cord injury with no motor or sensory function (i.e., ASIA-A) that does not involve penetrating injury (e.g., a gunshot wound) or complete severing of the spinal cord. Approval under HUD allows for commercialization under a Humanitarian Device Exemption (HDE) rather than a Pre-Market Approval (PMA) pathway, saving InVivo an estimated two to three years and tens of millions of dollars in clinical trials.
We note devices eligible for HUD designations are developed to treat rare diseases or conditions that affects fewer than 4,000 individuals in the U.S. per year. According to the National Spinal Cord Injury Statistical Center (NSCISC), an estimated 12,000 individuals will become fully or partially paralyzed each year due to spinal cord injury. NSCISC data show that approximately 22% of these individuals will have complete tetraplegia and 25% will have complete paraplegia. That would bring the proposed population down to 5,640 individuals. If we assume that half of this population does not have a penetrating injury or the complete severing of the spinal cord, investors can see that InVivo is well below the 4,000 maximum eligible population. On a side note, we fully expect that if approved with the proposed label, InVivo's device will be used, and could even be approved, for a much wider patient population than just the medically plausible subset outlined in the HUD request.
… And Approves the IDE
In July 2011, InVivo Therapeutics filed an Investigational Device Exemption (IDE) application for its biocompatible polymer scaffolding (BPS) device to treat acute spinal cord injuries. It's been almost two years since the original IDE application, but the agency finally granted approval allowing the start of the first human trial with the BPS on April 5, 2013. We remind investors that in April 2012, the agency confirmed that the BPS will be regulated as a Class III medical device.
The proposed study will seek to enroll five patients with acute thoracic injuries in an open-label design to take place at two level one trauma centers, one in Boston at Massachusetts General Hospital (MGS) and the other in Philadelphia. The primary outcome of the study will be to assess signs of improvement below the level of the spinal cord injury. InVivo will use standardized American Spinal Injury Association (ASIA) scoring to assess efficacy over a year-long period. We expect enrollment and treatment to take approximately two to three months, with data beginning to dribble out a month later thanks to the open-label design. Patient follow-up will last twelve months. The cost will be around $1.5 million.
InVivo believes that all data will be in hand roughly 15 months after initiation. Assuming the trial begins in the next few months, that means we should have final results in late 2014, allowing for the HDE filing hopefully before the end of the year 2014. The FDA would then review the HDE application and have 75 days to respond. If all goes well, InVivo would be in position to start marketing its biocompatible polymer scaffolding product for acute spinal cord injury as early as the second quarter 2015.
We expect InVivo to look to duplicate positive results in patients with cervical injury. If the product is approved by the FDA, we suspect that InVivo will need to expand manufacturing capacity, and establish sales, marketing and distribution channels to sell the product. InVivo plans to market and sell the product through a direct sales force in the U.S. on its own. Approval under the HDE pathway will also protect InVivo from competition with a similar device for seven years.
Warrant Exchange to Facilitate Uplisting
InVivo's stated goal is to move from the OTC to a national exchange, either the Nasdaq or NYSE-MKT. To do that, the company must meet certain listing requirements around market value, tangible assets, stock price, and stockholders' equity. As of today, the company meets all requirements for listing on the Nasdaq-CM or NYSE-MKT except stockholders' equity of greater than $4.0 million.
InVivo exited 2012 (Form 10-K) with $13.4 million in cash and equivalents and $16.1 million in total assets. Total liabilities at year end 2012 were $18.4 million, thus resulting in negative stockholders' deficit of $2.3 million. However, we note of the $18.4 million in total liabilities, $14.6 million was a non-cash derivative warrant liability resulting from approximately 15.3 million warrants outstanding at year-end 2012 with anti-dilution provisions. The warrant liability is revalued each quarter and increases as InVivo's stock price increases. InVivo's stock closed at $1.74 per share on Dec. 31, 2012. On March 28, 2013, the last day of trading for the first quarter 2013, the stock closed at $2.39 per share -- a 37% increase. Therefore, when InVivo files its Form 10-Q for the first quarter 2013, we expect this non-cash liability to be above $20.0 million, further reducing the stockholders' equity number and keeping InVivo from uplisting to the Nasdaq or NYSE-MKT.
On April 8, 2013, InVivo announced an offer to exchange the roughly 15.0 million warrants ("2010 warrants") that remained outstanding as of March 31, 2013, for new warrants that no longer have the anti-dilution provision. The anti-dilution provision allows for the reset of the exercise price of the warrant to a new lower price if the company raises cash at prices below the exercise price of the warrants. This is the "liability" that must be recorded on the balance sheet. The liability increases as the stock price increases farther above $1.40 per share where the majority of the warrants are exercisable (see SEC filing). The new warrants would not have an anti-dilution provision. In return, InVivo would expend the duration of the warrants by two years so that they all expire in the fourth quarter of 2017 instead of 2015.
Warrants Subject to Exchange Offer
Click to enlarge image.
The exchange period will remain active until May 6, 2013. Given the stock price is currently above $3.00 per share, the odds of the anti-dilution provision being activated are low, especially now that InVivo has been granted HUD and the IDE has been cleared for the biopolymer scaffolding. Thus, we think the exchange is attractive to the "2010 warrant" holders and expect greater than 90% tender. Plus, the ultimate goal of the exchange is to facilitate an uplisting to a national exchange, something that both share and warrant holders clearly would like to see.
If we remove all derivative liability from the balance sheet as of today, stockholders' equity would be positive to the tune of around $12.5 million. This would allow for the company to qualify for listing on either the Nasdaq-CM or NYSE-MKT. We believe once complete, InVivo will look to move quickly with listing on either exchange. As of March 6, 2013, the basic share count stood at 66.1 million, putting the basic market capitalization over $200 million. Listing on a national exchange with a market capitalization over $200 million should allow for significantly improved institutional ownership -- something InVivo's stock is sorely missing.
Stock Remains Attractive
We see the opportunity in acute thoracic spinal cord injury, as defined under the HUD application, as a peak $240 million opportunity. This includes treating the maximum 4,000 patients at a price of roughly $60,000 per treatment. We think InVivo could actually charge more for the BPS device. Data from the NSCISC shows that the average cost to care for a spinal cord injury patient in the first year of the injury ranges between $335,000 and $1,025,000. For a 25 year old with complete tetraplegia, the lifetime cost of care is an estimated $4.5 million. For a complete paraplegic, it's an estimated $2.5 million. We remind investors that if the IDE trial succeeds, InVivo could be on the market selling its BPS device into this estimated $250 million opportunity as soon as mid-2015.
Now the upside to the story: The hydrogel and the BPS-hNSC. With the hydrogel for SCI, we estimate that nearly all of the 12,000 acute injury patients per year could be eligible for treatment. With a premium price of $75,000 per surgery, InVivo is looking at an estimated $900 million opportunity. In peripheral nerve pain, above we note an estimated 3.2 million procedures per year. With as little as 5% market share and a yearly price of only $10,000, InVivo is looking at another $1.6 billion market. That alone makes InVivo an interesting long-term investment.
But what really gets us excited is the potential for use of the BPS seeded with autologous human neural stem cells. There are an estimated 200,000 chronic spinal cord injury patients in the U.S. If InVivo can treat just 20% of these patients, with an estimated price of around $100,000 per surgery, the market opportunity would be approximately $4.0 billion. We see the stock with $5.00 per share based on appropriately discounting this opportunity.
Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Jason Napodano, CFA. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.